檢體採集卡市場:2023年至2028年預測
市場調查報告書
商品編碼
1410144

檢體採集卡市場:2023年至2028年預測

Specimen Collection Cards Market - Forecasts from 2023 to 2028

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

檢體採集卡市場預計在預測期內複合年成長率為 5.87%。

檢體採集卡是為了方便血液、唾液、口腔細胞、尿液等各種生物樣本的採集和運輸而特意製作的。它在保持 DNA 完整性方面也非常出色,即使在常溫下長期保存後也能確保 DNA 的快速洗脫。檢體卡採集的應用涵蓋廣泛的領域,包括新生兒篩檢(NBS)、傳染病檢查、治療藥物監測、法醫學、研究、福祉/健康監測以及各種其他應用。

病理學的進步將推動檢體採集卡市場的成長。

檢體採集卡因其方便有效地保存血液、唾液、口腔細胞、尿液等各種生物樣本而被醫學實驗室和病理學科學家廣泛使用。這些卡可實現安全高效的樣本採集、運輸和存儲,使其成為診斷測試的重要工具。對檢體採集卡的需求不斷增加,因為越來越多的不同領域的科學家認知到這些卡的價值,包括非侵入性採樣和可靠的 DNA 洗脫。例如,2020年,加拿大醫學和病理科學家人數激增至19,757人,與前一年同期比較大幅增加6.8%。

法醫學中心設施正在推動檢體採集卡市場的發展。

法醫學中心使用檢體採集卡在安全儲存和運輸從犯罪現場、受害者和嫌疑人收集的生物證據方面發揮重要作用。這些卡片可以輕鬆、非侵入性地對血液、唾液和其他體液進行採樣,確保 DNA 和其他生物標記物的完整性,從而實現準確的分析和證據記錄。由於刑事調查對科學進步的需求不斷增加,法醫學中心正在快速發展。據內政部稱,2023年5月,印度政府在古瓦哈提建立了第10個國家法醫學大學(NFSU)中心,使其成為全球第11個中心。

政府的措施和投資正在推動檢體採集卡市場的發展。

由於政府旨在改善醫療服務和加強疾病早期檢測的診斷中心的舉措和投資,檢體採集卡行業取得了顯著成長。檢體採集卡在這些情況下發揮重要作用,因為它們可以實現高效可靠的樣本採集並確保診斷測試的準確性。例如,2021年11月,英國政府向NHS撥款約3.37億美元資金,專門用於加強診斷服務的技術基礎設施。這項投資的主要目標是簡化 NHS 內訂購、進行和審查醫療檢查的整個流程。

預計亞太地區將主導市場。

由於病理學研究人員數量大幅增加以及對可靠、高效的檢體採集方法的需求急劇增加,亞太地區在檢體採集卡市場中佔據了主要佔有率。例如,根據世界衛生組織(WHO)統計,2020年,印度醫學和病理科學家人數激增至635,500人,較2018年大幅增加65%。此外,該地區各國政府正在進行大量投資,以提高診斷中心的能力並加強醫療基礎設施。例如,2020年6月,中國當局發起一項計劃,採集全國7億男性和女性的血液樣本並建立基因資料庫。

替代樣本的存在限制了檢體採集卡市場的成長。

來自液體採集系統和自動採樣設備等替代樣本採集方法的激烈競爭正在限制檢體採集卡行業的成長。由於這些替代方案具有多種優勢,包括易於使用、提高通量以及適合特定分析物,因此醫學和研究界的偏好可能會發生變化,對檢體採集卡的需求也可能會發生變化,這可能會影響整體。

企業產品

  • EasiCollect Plus: QIAGEN 推出了 EasiCollect Plus,這是一款先進的口腔樣本採集設備,具有整合的可閉合設計,可確保一致且可靠的樣本傳輸,同時提供安全運輸。這種先進的解決方案提供了一種使用者友好且無縫的口腔樣本採集方法,確保了運輸過程中樣本的完整性,並顯著提高了各種應用中樣本分析的準確性和效率。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章檢體採集卡市場:依檢體類型

  • 介紹
  • 唾液
  • 尿
  • 口腔細胞
  • 其他

第6章檢體採集卡市場:依材料分類

  • 介紹
  • 棉纖維素基
  • 纖維基
  • 其他

第7章檢體採集卡市場:分產品

  • 介紹
  • Whatman 903
  • Ahlstrom 226
  • FTA
  • 其他

第8章檢體採集卡市場:依應用分類

  • 介紹
  • 新生兒篩檢(NBS)
  • 傳染病檢查
  • 治療藥物監測
  • 法醫學
  • 研究
  • 福祉/健康監測
  • 其他用途

第9章檢體採集卡市場:分地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第10章競爭環境及分析

  • 主要企業及策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 供應商競賽矩陣

第11章 公司簡介

  • QIAGEN
  • PerkinElmer Inc.
  • Euroimmun
  • Eastern Business Forms, Inc.
  • Ahlstrom
  • ARCHIMED Life Science GmbH
  • GenTegra LLC
  • FortiusBio
  • CENTOGENE NV
簡介目錄
Product Code: KSI061615819

The specimen collection card market is estimated to grow at a CAGR of 5.87% during the forecast period.

Specimen collection cards are purposefully crafted to facilitate the collection and transportation of various bio-samples, such as blood, saliva, buccal cells, and urine. Also, they excel in preserving DNA integrity, ensuring its swift elution even after extended periods of storage at ambient temperatures. The applications of specimen card collection encompass a wide range of areas, including Newborn Screening (NBS), infectious diseases testing, therapeutic drug monitoring, forensics, research, well-being/health monitoring, and other diverse applications.

Improved pathology bolsters the specimen collection cards market growth.

Specimen collection cards are extensively used in medical laboratories and pathology by scientists due to their convenience and effectiveness in preserving various biological samples like blood, saliva, buccal cells, and urine. These cards enable safe and efficient sample collection, transportation, and storage, making them an indispensable tool for diagnostic testing purposes. The increasing demand for specimen collection cards can be attributed to the growing number of scientists engaged in diverse fields of research, who recognize the value of these cards for non-invasive sampling, and reliable DNA elution. For instance, In 2020, the number of medical and pathology scientists in Canada surged to 19,757, marking a notable 6.8% increase compared to the previous year.

Improved forensic science centres' establishments drive the specimen collection card market.

Specimen collection cards are utilized in forensic science centres for their crucial role in securely preserving and transporting biological evidence collected from crime scenes, victims, or suspects. These cards enable easy, non-invasive sampling of blood, saliva, and other bodily fluids, ensuring the integrity of DNA and other biomarkers for accurate analysis and evidence documentation. Forensic science centres are experiencing rapid growth due to increasing demand for scientific advancements in criminal investigations. According to the Ministry of Home Affairs, in May 2023, the Government of India established its 10th National Forensic Science University (NFSU) centre in Guwahati, also making it the world's 11th centre.

Government initiatives and investments drive the specimen collection cards market.

The specimen collection cards industry is experiencing significant growth driven by government initiatives and investments aimed at bolstering diagnostic centres with a focus on improving healthcare services and enhancing early disease detection. Specimen collection cards play a crucial role in this context, as they enable efficient and reliable sample collection, and ensure the accuracy of diagnostic tests. For instance, in November 2021, the UK government allocated approximately $337 million in funding to the NHS, dedicated to enhancing the technological infrastructure of its diagnostic services. The primary objective of this investment was to streamline the entire process of ordering, performing, and reviewing medical tests within the NHS (National Health Service).

Asia-Pacific is expected to dominate the market.

Asia-Pacific will hold a significant share of the specimen collection card market due to a substantial increase in the number of pathology scientists, contributing to a surge in demand for reliable and efficient sample collection methods. For instance, according to the World Health Organization, in 2020, the number of medical and pathology scientists in India surged to 635,500, marking a remarkable 65% increase from the figures recorded in 2018. Additionally, governments in the region have undertaken significant investments to boost diagnostic centres' capabilities and enhance healthcare infrastructure For instance, in June 2020, Chinese authorities launched an initiative to collect blood samples of males 700 million males including men and boys across the country to create a genetic database that would provide the government with a sophisticated tool for their advancing high-tech surveillance capabilities.

Alternatives availability restrains the specimen collection cards market growth.

The presence of stiff competition from alternative sample collection methods, including liquid-based collection systems and automated sampling devices is contracting the specimen collection cards industry growth. These alternative methods offer diverse advantages, such as enhanced ease of use, higher throughput, and compatibility with specific analytes, leading to potential shifts in preferences within the medical and research communities, which could in turn influence the overall demand for specimen collection cards.

Key Developments

  • February 2023: Capitainer AB introduced an innovative self-sampling product to the market, boasting the capability to collect five times more blood than its previous version. This advancement allows for a wider range of analyses and testing options. Additionally, the new product has been designed to be more user-friendly, simplifying the implementation process for laboratories. Its improved features hold the potential to revolutionize blood sample collection and analysis, offering enhanced efficiency and flexibility in diagnostic and research.
  • July 2022: Rhinostics introduced the revolutionary VERIstic, a groundbreaking collection device that redefines small-volume blood collection. It seamlessly combines the proven method of capillary blood collection with an integrated, automation-ready cap, streamlining the process and offering significant benefits for time, cost, and workflow efficiency in laboratories. For patients and clinicians alike, the collection procedure is now rapid, simple, and comfortable, enhancing the overall experience and facilitating a hands-free workflow from sample collection to laboratory analysis.
  • May 2022: Abson Diagnostics and Becton, Dickinson and Company (BD) have further strengthened their strategic collaboration, aiming to spearhead innovation in blood sample collection, with a specific focus on exploring new care settings. The expanded partnership aims to empower patients by allowing them to conveniently collect blood samples at home for diagnostic testing, offering greater accessibility and ease of healthcare services. This advancement promises to revolutionize the way diagnostic testing is conducted, bringing the benefits of home-based blood sample collection to patients and healthcare providers.

Company Products

  • EasiCollect Plus: QIAGEN introduces EasiCollect Plus, an advanced buccal sample collection device that boasts an integrated and closable design, ensuring both consistent and reliable sample transfer while providing secure transportation. This advanced solution offers a user-friendly and seamless approach to collecting buccal samples, guaranteeing their integrity during transportation, and significantly improving the precision and efficiency of sample analysis across a range of applications.

Segmentation

By Type of Specimen

  • Blood
  • Saliva
  • Urine
  • Buccal Cells
  • Others

By Material

  • Cotton & Cellulose-based
  • Fiber-based
  • Others

By Product

  • Whatman 903
  • Ahlstrom 226
  • FTA
  • Others

By Application

  • New Born Screening (NBS)
  • Infectious Diseases Testing
  • Therapeutic Drug Monitoring
  • Forensics
  • Research
  • Wellbeing/Health Monitoring
  • Other Applications

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SPECIMEN COLLECTION CARDS MARKET, BY TYPE OF SPECIMEN

  • 5.1. Introduction
  • 5.2. Blood
  • 5.3. Saliva
  • 5.4. Urine
  • 5.5. Buccal Cells
  • 5.6. Others

6. SPECIMEN COLLECTION CARDS MARKET, BY MATERIAL

  • 6.1. Introduction
  • 6.2. Cotton & Cellulose-based
  • 6.3. Fiber-based
  • 6.4. Others

7. SPECIMEN COLLECTION CARDS MARKET, BY PRODUCT

  • 7.1. Introduction
  • 7.2. Whatman 903
  • 7.3. Ahlstrom 226
  • 7.4. FTA
  • 7.5. Others

8. SPECIMEN COLLECTION CARDS MARKET, BY APPLICATION

  • 8.1. Introduction
  • 8.2. New Born Screening (NBS)
  • 8.3. Infectious Diseases Testing
  • 8.4. Therapeutic Drug Monitoring
  • 8.5. Forensics
  • 8.6. Research
  • 8.7. Wellbeing/Health Monitoring
  • 8.8. Other Applications

9. SPECIMEN COLLECTION CARDS MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. The Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. QIAGEN
  • 11.2. PerkinElmer Inc.
  • 11.3. Euroimmun
  • 11.4. Eastern Business Forms, Inc.
  • 11.5. Ahlstrom
  • 11.6. ARCHIMED Life Science GmbH
  • 11.7. GenTegra LLC
  • 11.8. FortiusBio
  • 11.9. CENTOGENE N.V.